OBJECTIVE: To describe cancer screening rates for cancer survivors and compare them with those for matched controls. DESIGN: Population-based, retrospective study with individuals linked across administrative databases. SETTING: Ontario. PARTICIPANTS: Survivors of breast (n = 11 219), colorectal (n = 4348), or endometrial (n = 3473) cancer, or Hodgkin lymphoma (HL) (n = 2071) matched to general population controls. Survivors were those who had completed primary treatment and were on "well" follow-up. The study period was 4 years (1 to 5 years from the date of cancer diagnosis). MAIN OUTCOME MEASURES: Never versus ever screened (in the 4-year study period) for breast cancer, colorectal cancer (CRC), and cervical cancer and never versus ever received (during the study period) a periodic health examination; rates were compared between cancer survivors and controls. Random effects models were used to estimate odds ratios and 95% CIs. RESULTS: Sixty-five percent of breast cancer survivors were never screened for CRC and 40% were never screened for cervical cancer. Approximately 50% of CRC survivors were never screened for breast or cervical cancer. Thirty-two percent of endometrial cancer survivors were never screened for breast cancer and 66% were never screened for CRC. Forty-four percent of HL survivors were never screened for breast cancer, 77% were never screened for CRC, and 32% were never screened for cervical cancer. Comparison with matched controls showed a mixed picture, with breast and endometrial cancer survivors more likely, and CRC and HL survivors less likely, than controls to be screened. CONCLUSION: There is concern about the preventive care of cancer survivors despite frequent visits to both oncology specialists and family physicians during the "well" follow-up period.
OBJECTIVE: To describe cancer screening rates for cancer survivors and compare them with those for matched controls. DESIGN: Population-based, retrospective study with individuals linked across administrative databases. SETTING: Ontario. PARTICIPANTS: Survivors of breast (n = 11 219), colorectal (n = 4348), or endometrial (n = 3473) cancer, or Hodgkin lymphoma (HL) (n = 2071) matched to general population controls. Survivors were those who had completed primary treatment and were on "well" follow-up. The study period was 4 years (1 to 5 years from the date of cancer diagnosis). MAIN OUTCOME MEASURES: Never versus ever screened (in the 4-year study period) for breast cancer, colorectal cancer (CRC), and cervical cancer and never versus ever received (during the study period) a periodic health examination; rates were compared between cancer survivors and controls. Random effects models were used to estimate odds ratios and 95% CIs. RESULTS: Sixty-five percent of breast cancer survivors were never screened for CRC and 40% were never screened for cervical cancer. Approximately 50% of CRC survivors were never screened for breast or cervical cancer. Thirty-two percent of endometrial cancer survivors were never screened for breast cancer and 66% were never screened for CRC. Forty-four percent of HL survivors were never screened for breast cancer, 77% were never screened for CRC, and 32% were never screened for cervical cancer. Comparison with matched controls showed a mixed picture, with breast and endometrial cancer survivors more likely, and CRC and HL survivors less likely, than controls to be screened. CONCLUSION: There is concern about the preventive care of cancer survivors despite frequent visits to both oncology specialists and family physicians during the "well" follow-up period.
Authors: Sang Min Park; Chong Taik Park; Sang Yoon Park; Duk-Soo Bae; Joo Hyun Nam; Chi-Heum Cho; Jong Min Lee; Craig C Earle; Young Ho Yun Journal: Cancer Causes Control Date: 2009-08-18 Impact factor: 2.506
Authors: Claire F Snyder; Craig C Earle; Robert J Herbert; Bridget A Neville; Amanda L Blackford; Kevin D Frick Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Claire F Snyder; Kevin D Frick; Kimberly S Peairs; Melinda E Kantsiper; Robert J Herbert; Amanda L Blackford; Antonio C Wolff; Craig C Earle Journal: J Gen Intern Med Date: 2009-01-21 Impact factor: 5.128
Authors: Winson Y Cheung; Bridget A Neville; Danielle B Cameron; E Francis Cook; Craig C Earle Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Lacey Loomer; Kevin C Ward; Evelyn A Reynolds; Silke A von Esenwein; Joseph Lipscomb Journal: J Cancer Surviv Date: 2019-06-06 Impact factor: 4.442
Authors: Crystal S Denlinger; Robert W Carlson; Madhuri Are; K Scott Baker; Elizabeth Davis; Stephen B Edge; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Elizabeth Kvale; Terry S Langbaum; Jennifer A Ligibel; Mary S McCabe; Kevin T McVary; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Tracey O'Connor; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2014-01 Impact factor: 11.908
Authors: Bridgette Thom; Annelies H Boekhout; Stacie Corcoran; Roberto Adsuar; Kevin C Oeffinger; Mary S McCabe Journal: J Oncol Pract Date: 2019-01-07 Impact factor: 3.840
Authors: Mary Playdon; Leah M Ferrucci; Ruth McCorkle; Kevin D Stein; Rachel Cannady; Tara Sanft; Brenda Cartmel Journal: J Cancer Surviv Date: 2016-01-07 Impact factor: 4.442